Current Programs

Polpharma Biologics has a robust and expanding pipeline of biosimilars currently in development to treat a number of conditions across major therapeutic areas. Our proprietary cell line development platform and highly efficient R&D workflows have set the stage for the development of six biosimilar candidates, with one currently in phase III clinical trials. We are highly focused on advancing and expanding our product portfolio to increase patient access to these much-needed therapies and are open to partnering with other organizations to co-develop or commercialize our biosimilars.

 

Biosimilars Pipeline

Code / Molecule
Originator
Type
Therapeutic Area
Ranibizumab*
Lucentis
Biosimilar
Ophthalmology
PB006 / Natalizumab
Tysabri
Biosimilar
Multiple Sclerosis
PB007 / Ustekinumab
Stelara
Biosimilar
Immunology
PB014
Not disclosed
Biosimilar
Oncology
PB015
Not disclosed
Biosimilar
Oncology
PB016
Not disclosed
Biosimilar
Immunology
Early Tech Dev
Late Tech Dev
PhI
PhIII
Submission
Approval